Cyclacel Pharmaceuticals, Inc.

Symbol: CYCCP




Market price today

  • -0.0732

    P/E Ratio

  • -0.0021

    PEG Ratio

  • 2.87M

    MRK Cap

  • 0.00%

    DIV Yield

Cyclacel Pharmaceuticals, Inc. (CYCCP) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Spiro George Rombotis
Full-time employees:12
City:Berkeley Heights
Address:200 Connell Drive

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

General Outlook

In simple terms, Cyclacel Pharmaceuticals, Inc. has 0.137 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.058% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -61.555%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -53.857%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -2.569% return, is a testament to Cyclacel Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Cyclacel Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -3.095%. Furthermore, the proficiency of Cyclacel Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -40.144% return on capital employed.

Stock Prices

Cyclacel Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $19.4, while its low point bottomed out at $19.4. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Cyclacel Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing CYCCP liquidity ratios reveals its financial health of the firm. The current ratio of 91.21% gauges short-term asset coverage for liabilities. The quick ratio (77.33%) assesses immediate liquidity, while the cash ratio (41.39%) indicates cash reserves.

Current Ratio91.21%
Quick Ratio77.33%
Cash Ratio41.39%

Profitability Ratios

CYCCP profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -6178.57% underscores its earnings before tax deductions. The effective tax rate stands at 12.83%, revealing its tax efficiency. The net income per EBT, 87.17%, and the EBT per EBIT, 100.38%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -6155.48%, we grasp its operational profitability.

Pretax Profit Margin-6178.57%
Effective Tax Rate12.83%
Net Income per EBT87.17%
EBT per EBIT100.38%
EBIT per Revenue-6155.48%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.91, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding77
Operating Cycle2548.92
Days of Payables Outstanding3269
Cash Conversion Cycle-720
Receivables Turnover0.14
Payables Turnover0.11
Fixed Asset Turnover4.12
Asset Turnover0.05

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -18.87, and free cash flow per share, -18.87, depict cash generation on a per-share basis. The cash per share value, 3.96, showcases liquidity position. A payout ratio of -0.01 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, -38.36, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-18.87
Free Cash Flow per Share-18.87
Cash per Share3.96
Payout Ratio-0.01
Operating Cash Flow Sales Ratio-38.36
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-435.46
Capital Expenditure Coverage Ratio-2685.33
Dividend Paid and Capex Coverage Ratio-77.84
Dividend Payout Ratio0.09

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.42%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.75%, and total debt to capitalization, 5.75%, ratios shed light on its capital structure. An interest coverage of 239.38 indicates its ability to manage interest expenses.

Debt Ratio0.42%
Debt Equity Ratio0.06
Long Term Debt to Capitalization5.75%
Total Debt to Capitalization5.75%
Interest Coverage239.38
Cash Flow to Debt Ratio-435.46
Company Equity Multiplier14.51

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.49, provides a glimpse into top-line earnings distributed across each share. Net income per share, -26.51, reflects the portion of profit attributed to each share. The book value per share, 0.71, represents the net asset value distributed per share, while the tangible book value per share, 0.71, excludes intangible assets.

Revenue Per Share0.49
Net Income Per Share-26.51
Book Value Per Share0.71
Tangible Book Value Per Share0.71
Shareholders Equity Per Share0.71
Interest Debt Per Share0.04
Capex Per Share-0.01

Growth Ratios

EBIT growth, -9.56%, and operating income growth, -9.56%, offer insights into operational profitability progression. The net income growth, -6.40%, showcases bottom-line expansion, and the EPS growth, 17.75%, measures the growth in earnings per share.

Gross Profit Growth1315.63%
EBIT Growth-9.56%
Operating Income Growth-9.56%
Net Income Growth-6.40%
EPS Growth17.75%
EPS Diluted Growth17.75%
Weighted Average Shares Growth29.38%
Weighted Average Shares Diluted Growth29.38%
Dividends per Share Growth-22.71%
Operating Cash Flow Growth22.64%
Free Cash Flow Growth22.64%
10-Year Revenue Growth per Share-97.12%
5-Year Revenue Growth per Share99.01%
10-Year Operating CF Growth per Share93.43%
5-Year Operating CF Growth per Share-70.89%
3-Year Operating CF Growth per Share42.18%
10-Year Net Income Growth per Share83.51%
5-Year Net Income Growth per Share-119.96%
3-Year Net Income Growth per Share23.96%
10-Year Shareholders Equity Growth per Share-99.84%
5-Year Shareholders Equity Growth per Share-97.18%
3-Year Shareholders Equity Growth per Share-99.48%
10-Year Dividend per Share Growth per Share-95.11%
5-Year Dividend per Share Growth per Share-28.93%
3-Year Dividend per Share Growth per Share-71.53%
Receivables Growth-48.00%
Inventory Growth100.00%
Asset Growth-67.98%
Book Value per Share Growth-96.97%
Debt Growth-65.09%
R&D Expense Growth18.23%
SGA Expenses Growth-8.99%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -1,069,323.95, captures the company's total value, considering both debt and equity. Income quality, 0.71, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 16.00, gauges operational efficiency, while the research and development to revenue, 5707.14%, highlights investment in innovation.

Enterprise Value-1,069,323.95
Income Quality0.71
Sales General and Administrative to Revenue16.00
Research and Development to Revenue5707.14%
Capex to Operating Cash Flow0.04%
Capex to Revenue-1.43%
Capex to Depreciation-19.35%
Stock-Based Compensation to Revenue350.71%
Graham Number20.63
Return on Tangible Assets-256.16%
Graham Net Net-3.08
Working Capital-717,000
Tangible Asset Value607,000
Net Current Asset Value-754,000
Average Receivables4,286,500
Average Payables3,052,000
Average Inventory-2,820,000
Days Sales Outstanding2549
Days Payables Outstanding41716

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.73, and the price to book ratio, 2.73, reflect the market's valuation relative to the company's book value. The price to sales ratio, 6.09, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.16, and price to operating cash flows, -0.10, gauge market valuation against cash flow metrics.

Price Book Value Ratio2.73
Price to Book Ratio2.73
Price to Sales Ratio6.09
Price Cash Flow Ratio-0.10
Enterprise Value Multiple-0.23
Price Fair Value2.73
Price to Operating Cash Flow Ratio-0.10
Price to Free Cash Flows Ratio-0.16
Price to Tangible Book Ratio3.74
Enterprise Value to Sales-2.55
Enterprise Value Over EBITDA0.04
EV to Operating Cash Flow0.07
Earnings Yield-992.88%
Free Cash Flow Yield-709.52%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Cyclacel Pharmaceuticals, Inc. (CYCCP) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.073 in 2024.

What is the ticker symbol of Cyclacel Pharmaceuticals, Inc. stock?

The ticker symbol of Cyclacel Pharmaceuticals, Inc. stock is CYCCP.

What is company IPO date?

IPO date of Cyclacel Pharmaceuticals, Inc. is 2005-11-30.

What is company current share price?

Current share price is 19.400 USD.

What is stock market cap today?

The market cap of stock today is 2871685.000.

What is PEG ratio in 2024?

The current -0.002 is -0.002 in 2024.

What is the number of employees in 2024?

In 2024 the company has 12.